|
1
|
Roodman D: Advances in bone biology: the
osteoclast. Endocr Rev. 17:308–332. 1996.PubMed/NCBI
|
|
2
|
Nair SP, Meghji S, Wilson M, Reddi K,
White P and Henderson B: Bacterially induced bone destruction:
mechanisms and misconceptions. Infect Immun. 64:2371–2380.
1996.PubMed/NCBI
|
|
3
|
Suda T, Takahashi N, Udagawa N, Jimi E,
Gillespie MT and Martin TJ: Modulation of osteoclast
differentiation and function by the new members of the tumor
necrosis factor receptor and ligand families. Endocr Rev.
20:345–357. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Boyle WJ, Simonet WS and Lacey DL:
Osteoclast differentiation and activation. Nature. 423:337–342.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Shuto T, Jimi E, Kukita T, Hirata M and
Koga T: Granulocytemacrophage colony stimulating factor suppresses
lipopolysaccharide-induced osteoclast-like cell formation in mouse
bone marrow cultures. Endocrinology. 134:831–837. 1994.
|
|
6
|
Abu-Amer Y, Ross FP, Edwards J and
Teitelbaum SL: Lipopolysaccharide-stimulated osteoclastogenesis is
mediated by tumor necrosis factor via its P55 receptor. J Clin
Invest. 100:1557–1565. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Islam S, Hassan F, Tumurkhuu G, et al:
Bacterial lipopolysaccharide induces osteoclast formation in RAW
264.7 macrophage cells. Biochem Biophys Res Commun. 360:346–351.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mörmann M, Thederan M, Nackchbandi I,
Giese T, Wagner C and Hänsch GM: Lipopolysaccharides (LPS) induce
the differentiation of human monocytes to osteoclasts in a tumour
necrosis factor (TNF) alpha-dependent manner: a link between
infection and pathological bone resorption. Mol Immunol.
45:3330–3337. 2008.PubMed/NCBI
|
|
9
|
Itoh K, Udagawa N, Kobayashi K, et al:
Lipopolysaccharide promotes the survival of osteoclasts via
toll-like receptor 4, but cytokine production of osteoclasts in
response to lipopolysaccharide is different from that of
macrophages. J Immunol. 170:3688–3695. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Takami M, Kim N, Rho J and Choi Y:
Stimulation by toll-like receptors inhibits osteoclast
differentiation. J Immunol. 169:1516–1523. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Orcel P, Feuga M, Bielakoff J and De
Vernejoul MC: Local bone injections of LPS and M-CSF increase bone
resorption by different pathways in vivo in rats. Am J Physiol.
264:E391–E397. 1993.PubMed/NCBI
|
|
12
|
Chiang CY, Kyritsis G, Graves DT and Amar
S: Interleukin-1 and tumor necrosis factor activities partially
account for calvarial bone resorption induced by local injection of
lipopolysaccharide. Infect Immun. 67:4231–4236. 1999.PubMed/NCBI
|
|
13
|
Ito HO, Shuto T, Takada H and Koga T, Aida
Y, Hirata M and Koga T: Lipopolysaccharides from Porphyromonas
gingivalis, Prevotella intermedia and Actinobacillus
actinomycetemcomitans promote osteoclastic differentiation in
vitro. Arch Oral Biol. 41:439–444. 1996.
|
|
14
|
Guo C, Hou GQ, Li XD, et al: Quercetin
triggers apoptosis of lipopolysaccharide (LPS)-induced osteoclasts
and inhibits bone resorption in RAW264.7 cells. Cell Physiol
Biochem. 30:123–136. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Halleen JM, Raisanen S, Salo JJ, et al:
Intracellular fragmentation of bone resorption products by reactive
oxygen species generated by osteoclastic tartrate-resistant acid
phosphatase. J Biol Chem. 274:22907–22910. 1999. View Article : Google Scholar
|
|
16
|
Angel NZ, Walsh N, Forwood MR, Ostrowski
MC, Cassady AI and Hume DA: Transgenic mice overexpressing
tartrate-resistant acid phosphatase exhibit an increased rate of
bone turnover. J Bone Miner Res. 15:103–110. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Reponen P, Sahlberg C, Munaut C, Thesleff
I and Tryggvason K: High expression of 92-kD type IV collagenase
(gelatinase B) in the osteoclast lineage during mouse development.
J Cell Biol. 124:1091–1102. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yu X, Huang Y, Collin-Osdoby P and Osdoby
P: Stromal cell-derived factor-1 (SDF-1) recruits osteoclast
precursors by inducing chemotaxis, matrix metalloproteinase-9
(MMP-9) activity, and collagen transmigration. J Bone Miner Res.
18:1404–1418. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wilson SR, Peters C, Saftig P and Brömme
D: Cathepsin K activity-dependent regulation of osteoclast actin
ring formation and bone resorption. J Biol Chem. 284:2584–2592.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ishikawa T, Kamiyama M, Tani-Ishii N, et
al: Inhibition of osteoclast differentiation and bone resorption by
cathepsin K antisense oligonucleotides. Mol Carcinog. 32:84–91.
2001. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kozloff KM, Quinti L, Patntirapong S,
Hauschka PV, Tung CH, Weissleder R and Mahmood U: Non-invasive
optical detection of cathepsin K-mediated fluorescence reveals
osteoclast activity in vitro and in vivo. Bone. 44:190–198. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lehenkari P, Hentunen TA, Laitala-Leinonen
T, Tuukkanen J and Väänänen HK: Carbonic anhydrase II plays a major
role in osteoclast differentiation and bone resorption by effecting
the steady state intracellular pH and Ca2+. Exp Cell
Res. 242:128–137. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li L, Pettit AR, Gregory LS and Forwood
MR: Regulation of bone biology by prostaglandin endoperoxide H
synthases (PGHS): a rose by any other name. Cytokine Growth Factor
Rev. 17:203–216. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ono K, Akatsu T, Murakami T, et al:
Involvement of cyclooxygenase-2 in osteoclast formation and bone
destruction in bone metastasis of mammary carcinoma cell lines. J
Bone Miner Res. 17:774–781. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ono K, Akatsu T, Kugai N, Pilbeam CC and
Raisz LG: The effect of deletion of cyclooxygenase-2, prostaglandin
receptor EP2, or EP4 in bone marrow cells on osteoclasts induced by
mouse mammary cancer cell lines. Bone. 33:798–804. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kellinsalmi M, Parikka V, Risteli J, et
al: Inhibition of cyclooxygenase-2 down-regulates osteoclast and
osteoblast differentiation and favours adipocyte formation in
vitro. Eur J Pharmacol. 572:102–110. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Armstrong AP, Tometsko ME, Glaccum M,
Sutherland CL, Cosman D and Dougall WC: A RANK/TRAF6-dependent
signal transduction pathway is essential for osteoclast
cytoskeletal organization and resorptive function. J Biol Chem.
277:44347–44356. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Crockett JC, Mellis DJ, Scott DI and
Helfrich MH: New knowledge on critical osteoclast formation and
activation pathways from study of rare genetic diseases of
osteoclasts: focus on the RANK/RANKL axis. Osteoporos Int. 22:1–20.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kong YY, Yoshida H, Sarosi I, et al: OPGL
is a key regulator of osteoclastogenesis, lymphocyte development
and lymph-node organogenesis. Nature. 397:315–323. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kim N, Odgren PR, Kim DK, Marks SC Jr and
Choi Y: Diverse roles of the tumor necrosis factor family member
TRANCE in skeletal physiology revealed by TRANCE deficiency and
partial rescue by a lymphocyte-expressed TRANCE transgene. Proc
Natl Acad Sci USA. 97:10905–10910. 2000. View Article : Google Scholar
|
|
31
|
Li J, Sarosi I, Yan XQ, et al: RANK is the
intrinsic hematopoietic cell surface receptor that controls
osteoclastogenesis and regulation of bone mass and calcium
metabolism. Proc Natl Acad Sci USA. 97:1566–1571. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Dougall WC, Glaccum M, Charrier K, et al:
RANK is essential for osteoclast and lymph node development. Genes
Dev. 13:2412–2424. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Feeley BT, Liu NQ, Conduah AH, et al:
Mixed metastatic lung cancer lesions in bone are inhibited by
noggin overexpression and RANK:Fc administration. J Bone Miner Res.
21:1571–1580. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Childs LM, Paschalis EP, Xing L, et al: In
vivo RANK signaling blockade using the receptor activator of
NF-kappaB:Fc effectively prevents and ameliorates wear
debris-induced osteolysis via osteoclast depletion without
inhibiting osteogenesis. J Bone Miner Res. 17:192–199. 2002.
View Article : Google Scholar
|
|
35
|
Kim H, Choi HK, Shin JH, et al: Selective
inhibition of RANK blocks osteoclast maturation and function and
prevents bone loss in mice. J Clin Invest. 119:813–825. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Poblenz AT, Jacoby JJ, Singh S and Darnay
BG: Inhibition of RANKL-mediated osteoclast differentiation by
selective TRAF6 decoy peptides. Biochem Biophys Res Commun.
359:510–515. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Pearson G, Robinson F, Beers Gibson T, et
al: Mitogen-activated protein (MAP) kinase pathways: regulation and
physiological functions. Endocr Rev. 22:153–183. 2001.PubMed/NCBI
|
|
38
|
Zhang W and Liu HT: MAPK signal pathways
in the regulation of cell proliferation in mammalian cells. Cell
Res. 12:9–18. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Pedram A, Razandi M and Levin ER:
Extracellular signalregulated protein kinase/Jun kinase cross-talk
underlies vascular endothelial cell growth factor-induced
endothelial cell proliferation. J Biol Chem. 273:26722–26728. 1998.
View Article : Google Scholar
|
